NCT06751524
Available
Not Applicable
Botensilimab and Balstilimab Expanded Access Program
Overview
- Phase
- Not Applicable
- Status
- Available
- Sponsor
- Agenus Inc.
Overview
Brief Summary
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Detailed Description
This EAP is available for indications where there is reasonable scientific basis for use. Availability will depend on territory eligibility.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The patient's disease is serious or life-threatening.
- •The patient has undergone appropriate standard treatments; there are no comparable or satisfactory alternative treatments for the disease or condition; the treatment is adjunct to an existing treatment option, and the treatment is not medically contra-indicated.
- •Sufficient efficacy and safety evidence exists to make a benefit-risk analysis consistent with this policy and the potential patient benefit justifies any potential risks of treatment.
- •Sufficient clinical data are available to identify an appropriate dose and treatment duration.
- •The patient's treating physician and qualified medical personnel at Agenus agree there is sufficient evidence to assume the potential benefit to the patient justifies potential risks.
- •The patient is not eligible for participation in an ongoing clinical trial of the investigational medicine, including lack of access due to geographic limitations.
- •Expanded Access will not adversely impact any clinical development program, in particular, the conduct of a pivotal clinical trial that is required for regulatory approval.
- •The request must be made by the patient's treating physician.
- •Note: Other defined Inclusion/Exclusion criteria may apply.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
No Longer Available
Not Applicable
Expanded Access to Bimatoprost (Durysta)NCT05338606AbbVie
Unknown
Not Applicable
Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaNCT06028594Regeneron Pharmaceuticals
Approved For Marketing
Not Applicable
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With InhibitorsHemophilia ANCT03154437Genentech, Inc.
Available
Not Applicable
Expanded Access to ElezanumabNCT04278235AbbVie
No Longer Available
Not Applicable
Expanded Access to EpcoritamabLymphomaNCT05692050AbbVie